

Appendix Table 1. Three major prognostic indicators of patients with and without comorbidities

| | Severe cases (%) | Cases with composite endpoints (%) | Fatality cases (%) |
|-----------------------|-------------------------|---|---------------------------|
| HTN (n=269) | 156 (58) | 101 (38) | 55 (20) |
| DM (n=74) | 41 (55) | 20 (27) | 15 (20) |
| HTN+DM (n=115) | 82 (71) | 52 (45) | 22 (19) |
| Others (n=573) | 222 (39) | 109 (19) | 73 (13) |
| Total (n=1031) | 501 (49) | 282 (27) | 165 (16) |

Abbreviations:

HTN: hypertension

DM: diabetes mellitus

Appendix Table 2. The odds ratio of case fatality rate for elderly patients, male patients, and patients with COPD, HTN, DM, CHD, stroke, cancer, smoking history

| | Number of patients (%) | OR (univariable regression) | 95% CI | P-value | OR (multivariable regression) | 95% CI | P-value | OR (multivariable regression) | 95% CI | P-value |
|------------------------|------------------------|-----------------------------------|------------|--------------|-------------------------------------|------------|--------------|-------------------------------------|------------|--------------|
| The elderly | 462 (44.8) | 3.33 | 2.33-4.76 | 0.000 | 2.94 | 2.00-4.33 | 0.000 | 2.95 | 2.00-4.33 | 0.000 |
| Male | 538 (52.2) | 2.86 | 1.98-4.13 | 0.000 | 2.47 | 1.65-3.70 | 0.000 | 2.45 | 1.64-3.66 | 0.000 |
| COPD | 39 (3.7) | 4.93 | 2.56-9.47 | 0.000 | 2.69 | 1.32-5.49 | 0.006 | 2.72 | 1.33-5.54 | 0.006 |
| HTN | 384 (37.2) | 1.59 | 1.14-2.23 | 0.007 | 1.05 | 0.72-1.54 | 0.800 | 1.02 | 0.69-1.51 | 0.927 |
| DM | 189 (18.3) | 1.36 | 0.91-2.04 | 0.139 | | | | 1.22 | 0.78-1.92 | 0.381 |
| CHD | 84 (8.1) | 2.61 | 1.59-4.28 | 0.000 | 2.04 | 1.18-3.55 | 0.011 | 1.98 | 1.14-3.45 | 0.016 |
| Stroke | 22 (2.1) | 2.51 | 1.01-6.26 | 0.048 | 2.70 | 1.00-7.31 | 0.050 | 2.68 | 0.99-7.25 | 0.053 |
| Cancer | 29 (2.8) | 5.26 | 2.49-11.12 | 0.000 | 8.01 | 3.55-18.07 | 0.000 | 8.14 | 3.60-18.38 | 0.000 |
| Smoking history | 105 (10.1) | 3.22 | 2.07-5.02 | 0.000 | 2.05 | 1.25-3.38 | 0.005 | 2.09 | 1.27-3.45 | 0.004 |

DM was excluded from the multivariable logistic regression analysis due to the fact that it showed no relation to case fatality in the univariable logistic regression analysis.

Boldface of P-value indicates statistical significance ($p \leq 0.05$).

Abbreviations:

CHD: coronary atherosclerotic heart disease

DM: diabetes mellitus

HTN: hypertension

Appendix Table 3. Comparison of illness condition among senile and non-senile patients with and without hypertension

| | Age < 65 | | | Age ≥ 65 | | |
|-------------------------------------|--|--|--------------|--|--|--------------|
| | non-hypertension (n=419) | hypertension (n=150) | P-value | non-hypertension (n=228) | hypertension (n=234) | P-value |
| Age (SD), y | 48.7 (11.5) | 55.2 (7.5) | 0.000 | 71.4 (5.6) | 73.4 (6.8) | 0.001 |
| Female (%) | 215 (51.3) | 67 (44.7) | 0.162 | 102 (44.7) | 109 (46.6) | 0.691 |
| OOS (SD), % | 94.7 (7.2) | 93.8 (6.1) | 0.171 | 92.6 (8.1) | 91.8 (8.5) | 0.316 |
| HR (SD), beats/min | 91.6 (16.5) | 92.6 (18.0) | 0.541 | 91.1 (17.3) | 90.8 (15.9) | 0.843 |
| SBP (SD), mmHg | 125.4 (17.5) | 134.2 (18.6) | 0.000 | 132.4 (17.8) | 138.9 (19.7) | 0.000 |
| DBP (SD), mmHg | 79.5 (11.5) | 82.7 (12.6) | 0.006 | 79.4 (12.4) | 81.3 (13.0) | 0.105 |
| MAP (SD), mmHg | 94.8 (12.3) | 99.8 (13.2) | 0.000 | 97.1 (13.1) | 100.5 (13.3) | 0.005 |
| NEU (SD), /μL | 4.3×10 ³ (3.1×10 ³) | 4.9×10 ³ (3.3×10 ³) | 0.037 | 5.1×10 ³ (3.3×10 ³) | 5.7×10 ³ (4.1×10 ³) | 0.072 |
| LYM (SD), /μL | 1.3×10 ³ (0.6×10 ³) | 1.2×10 ³ (0.6×10 ³) | 0.090 | 1.0×10 ³ (0.5×10 ³) | 1.0×10 ³ (0.5×10 ³) | 0.507 |
| PLT (SD), ×10³/μL | 240.4 (99.4) | 238.7 (99.9) | 0.859 | 227.6 (103.0) | 222.8 (95.8) | 0.604 |
| CRP (SD), mg/dL | 3.6 (5.5) | 4.2 (5.9) | 0.305 | 5.3 (5.4) | 6.6 (6.5) | 0.023 |
| IL-6 (SD), pg/ml | 22.0 (78.7) | 29.7 (54.9) | 0.321 | 53.0 (178.7) | 41.9 (72.3) | 0.450 |
| LDH (SD), U/L | 293.1 (175.2) | 308.3 (154.0) | 0.348 | 335.2 (191.5) | 375.7 (231.9) | 0.042 |
| D-dimer (SD), μg/ml | 2.0 (4.8) | 2.4 (4.7) | 0.427 | 3.9 (6.3) | 4.1 (6.7) | 0.670 |
| eGFR (SD), ml/min | 100.3 (17.7) | 93.3 (16.8) | 0.000 | 80.0 (17.1) | 71.7 (20.8) | 0.000 |
| CCIR (%) | 147 (35.1) | 73 (48.7) | 0.003 | 116 (50.9) | 165 (70.5) | 0.000 |
| CFR1^a (%) | 37 (8.8) | 14 (9.3) | 0.853 | 51 (22.4) | 63 (26.9) | 0.256 |
| CFR2^b (%) | 37 (25.2) | 14 (19.2) | 0.321 | 51 (44.0) | 63 (38.2) | 0.331 |

CFR1^a: The dead in the group/The total in the group

CFR2^b: The dead in the group /The severe cases in the group

Boldface of P-value indicates statistical significance ($p < 0.05$).

Abbreviations:

CCIR: case-critically ill rate

CFR: case-fatality rate

CRP: C-reactive protein

DBP: diastolic blood pressure

eGFR: glomerular filtration rate

HR: heart rate

IL-6: Interleukin 6

LDH: lactate dehydrogenase

LYM: lymphocyte

MAP: mean arterial pressure

NEU: neutrophil

OOS: oximeter oxygen saturation

PLT: platelet

SBP: systolic blood pressure

Appendix Table 4. Comparison of in-hospital treatment of CCB and prognosis among different groups

| | | CCB | non-CCB | P-value |
|---|----------------------------|-------------|----------------|------------------|
| Total (n=1031) | Age≥65y (%) | 125 (64) | 337 (40) | <0.001 |
| | Male (%) | 100 (51) | 438 (52) | 0.717 |
| | OOS (SD), % | 93.5 (6.3) | 93.5 (7.9) | 0.989 |
| | HTN (%) | 166 (85) | 218 (26) | <0.001 |
| | Other underlying diseases# | 86 (44) | 276 (33) | 0.004 |
| | CFR (%) | 32/196 (16) | 133/835 (16) | 0.891 |
| | LOS (SD), d | 23.7 (10.3) | 20.8 (10.0) | 0.001 |
| Low-risk* (n=328) | CFR (%) | 0/14 (0) | 10/314 (3) | 1.000 |
| | LOS (SD), d | 13.2 (7.5) | 17.9 (9.3) | 0.066 |
| Age≥65y (n=462) | CFR (%) | 27/125 (22) | 87/337 (26) | 0.350 |
| | LOS (SD), d | 26.0 (9.9) | 23.7 (9.0) | 0.033 |
| HTN (n=384) | CFR (%) | 30/166 (18) | 47/218 (22) | 0.398 |
| | LOS (SD), d | 24.5 (10.2) | 22.3 (10.1) | 0.067 |
| Severe cases** with IKF (n=73) | CFR (%) | 12/23 (52) | 32/50 (64) | 0.337 |
| | LOS (SD), d | 31.9 (6.3) | 28.6 (12.2) | 0.339 |
| Severe cases** without IKF (n=271) | CFR (%) | 13/57 (23) | 76/214 (36) | 0.069 |
| | LOS (SD), d | 26.5 (10.0) | 24.8 (9.9) | 0.338 |

refer to cases combining with any one of the underlying diseases including DM, CHD, COPD, cancer, and smoking history

* refer to cases with non-HTN, age<65y, and OOS>93

** refer to cases with OOS≤93

Boldface of P-value indicates statistical significance (p<0.05).

Abbreviations:

CCB: calcium channel blockers

CFR: case-fatality rate

COPD: chronic obstructive pulmonary disease

HTN: hypertension

IKF: impaired kidney function

LOS: length of stay

OOS: oximeter oxygen saturation

Appendix Table 5. Comparison of illness condition between patients with hypertension taking CCB and not taking CCB

| | CCB (n=166) | non-CCB (n=218) | P-value |
|----------------------------|--------------------|------------------------|----------------|
| Age (SD), y | 68.0 (10.6) | 65.1 (11.8) | 0.014 |
| Female (%) | 78 (46.9) | 98 (44.9) | 0.692 |
| DM (%) | 41 (24.7) | 74 (33.9) | 0.050 |
| CHD (%) | 29 (17.5) | 37 (17.0) | 0.898 |
| IKF (%) | 41 (24.7) | 35 (16.1) | 0.035 |
| Smoking history (%) | 18 (10.8) | 35 (16.1) | 0.142 |
| COPD (%) | 5 (3.0) | 12 (5.5) | 0.239 |
| Cancer (%) | 5 (3.0) | 5 (2.3) | 0.909 |
| RASI (%) | 31 (18.7) | 18 (8.3) | 0.002 |
| OOS (SD), % | 93.2 (6.0) | 92.1 (8.7) | 0.131 |
| HR (SD), beats/min | 90.7 (15.0) | 91.7 (18.8) | 0.543 |
| SBP (SD), mmHg | 138.5 (19.3) | 136.0 (19.4) | 0.216 |
| DBP (SD), mmHg | 82.9 (12.5) | 81.0 (13.0) | 0.160 |
| MAP (SD), mmHg | 101.4 (12.8) | 99.3 (13.5) | 0.131 |
| CRP (SD), mg/dL | 5.6 (6.5) | 5.7 (6.3) | 0.918 |
| LDH (SD), U/L | 346.4 (208.6) | 351.4 (206.7) | 0.814 |
| eGFR (SD), ml/min | 78.1 (22.6) | 81.7 (21.4) | 0.111 |
| CCIR (%) | 103 (62.0) | 135 (61.9) | 0.981 |
| CFR (%) | 30 (18.0) | 47 (21.5) | 0.398 |

Boldface of P-value indicates statistical significance ($p \leq 0.05$).

Abbreviations:

DM: diabetes mellitus

CHD: coronary atherosclerotic heart disease

IKF: impaired kidney function

OOS: oximeter oxygen saturation

HR: heart rate

SBP: systolic blood pressure

DBP: diastolic blood pressure

MAP: mean arterial pressure

CRP: C-reactive protein

LDH: lactate dehydrogenase

eGFR: glomerular filtration rate

CCIR: case-critically ill rate

CFR: case-fatality rate

SI conversion factors:

To convert NEU to $\times 10^9/L$, multiply values by 0.001.

To convert LYM to $\times 10^9/L$, multiply values by 0.001.

To convert PLT to $\times 10^9/L$, multiply values by 1.

To convert CRP to mg/L, multiply values by 10.

To convert LDH to $\mu\text{kat}/L$, multiply values by 0.0167.

To convert D-dimer to nmol/L, multiply values by 5.476.

Appendix Table 6. The odds ratio of case fatality rate for patients with hypertension taking CCB

| | OR (multivariate regression) | 95% CI | P-value |
|------------------------|---|---------------|------------------|
| Age | 1.05 | 1.02-1.08 | 0.001 |
| Male | 3.54 | 1.85-6.78 | <0.001 |
| Smoking history | 1.90 | 0.93-3.88 | 0.081 |
| DM | 0.85 | 0.46-1.59 | 0.617 |
| IKF | 2.33 | 1.22-4.48 | 0.011 |
| COPD | 1.00 | 0.31-3.18 | 0.994 |
| Cancer | 1.53 | 0.29-8.17 | 0.619 |
| RASI | 0.94 | 0.37-2.36 | 0.891 |
| CCB | 0.67 | 0.37-1.20 | 0.176 |

Boldface of P-value indicates statistical significance ($p < 0.05$).

Abbreviations:

CCB: calcium channel blockers

COPD: chronic obstructive pulmonary disease

DM: diabetes mellitus

IKF: impaired kidney function

RASI: renin-angiotensin-aldosterone system inhibitors

Appendix Table 7. The odds ratio of case fatality rate for severe cases without IKF

| | OR (univariable regression) | 95%CI | P-value | OR (multivariable regression) | 95%CI | P-value |
|-----------------|--------------------------------|------------|--------------|----------------------------------|------------|--------------|
| Age≥65y | 2.49 | 1.46-4.24 | 0.001 | 2.84 | 1.56-5.17 | 0.001 |
| Male | 2.41 | 1.39-4.20 | 0.002 | 2.52 | 1.36-4.67 | 0.003 |
| HTN | 0.58 | 0.34-0.97 | 0.038 | 0.64 | 0.33-1.22 | 0.174 |
| DM | 0.89 | 0.49-1.60 | 0.691 | | | |
| CHD | 2.24 | 1.02-4.93 | 0.045 | 2.47 | 1.01-6.03 | 0.047 |
| COPD | 1.86 | 0.65-5.29 | 0.247 | | | |
| Smoking history | 2.00 | 0.97-4.13 | 0.062 | | | |
| Cancer | 10.13 | 2.14-47.93 | 0.004 | 15.76 | 2.93-84.78 | 0.001 |
| CCB | 0.54 | 0.27-1.06 | 0.072 | 0.42 | 0.18-0.99 | 0.046 |

DM, COPD, and smoking history were excluded from the multivariable logistic regression analysis due to the fact that they showed no relation to case fatality in the univariable logistic regression analysis.

Boldface of P-value indicates statistical significance (p<0.05).

Abbreviations:

CCB: calcium channel blockers

CHD: coronary atherosclerotic heart disease


COPD: chronic obstructive pulmonary disease

DM: diabetes mellitus

HTN: hypertension

Summarized mode pattern related to hypertension, ACE2, LDH, and eGFR

A large number of published studies demonstrated that LDH was the primary laboratory indicator for early prediction of COVID-19 progression and death. A Hangzhou study published online found that LDH was the only laboratory indicator that showed a significant change in hospitalized patients after antiviral treatment, indicating that the change in this indicator was related to the viral load.^[8] An Iran and a Brazilian study showed that the average levels of LDH of COVID-19 inpatients were 616.77 ± 314.22 U/L and 948 ($810.0-1139.8$) U/L respectively,^[20, 21] which were significantly higher than the results shown in Europe, America, Eastern Asia and our retrospective cohort study (323.32 ± 192.77 U/L). The differences suggest that the elevation of LDH level may be quite different among different ethnic groups, and the absolute value of LDH may be in connection with the expression of ACE2 and viral tolerance of patients themselves. Based on the above findings, we summarized the mode pattern associated with hypertensive patients in aggravated condition and ACE2 expression.



Abbreviations:

HTN: hypertension

ACE2: angiotensin-converting enzyme 2

LDH: lactate dehydrogenase

eGFR: glomerular filtration rate